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Introduction
Cytomegalovirus (CMV) is an opportunistic pathogen 
that, after the primary infection, causes lifelong latent in-
fection without any clinical manifestations in immunocom-
petent organisms. It causes severe diseases in weakened 
organisms, namely, newborns, patients receiving antitu-
mor chemotherapy, transplant recipients and HIV patients. 
CMV has some mechanisms by which it avoids the detection 
and destruction of the host immune system [1]. A CMV is 
a ubiquitous virus. Numerous researchers all over the world 
have obtained data indicating that the population has a large 
number of virus carriers and individuals with a hidden form 
of CMV. The proof of human infection is the presence of 
CMV antibodies in the body. There is information about the 
wide spread of CMV in the human population, the upward 
trend, the associated morbidity, and its increasing impor-
tance in human pathology [2, 3, 4, 5, 6]. Most of the world 
population (65 to 90%) is infected with a pathogen through-
out life. The infestation percentage depends on the socio-
economic status, geographical location and education [7]. It 
has been observed that seropositivity and virus carriage are 
more common in developing countries.
According to the decision of the WHO European Office, 
cytomegalovirus infection (CMVI) is included in the list of 
“new and mysterious diseases that determine the future of 
infectious diseases” [8]. The relevance of CMV infection is 
that it is a widespread pathology, and due to its ability to 
“disguise” in the human body, it remains unnoticed until 
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Abstract
Background: About one century ago, was found and described a new virus, which, due to its particular way of damaging cells, was called cytomegalovirus. 
Human is the only natural source of cytomegalovirus infection. The relevance is that it is a widespread pathology, and due to its ability to “disguise” in 
the human body, remains unnoticed until the “defect” appears in the body’s immune system. It is especially dangerous for pregnant women, children and 
people with immunodeficiency. It is one of the most common infections that cause pathology in the fetus and newborns, which, in turn, leads to serious 
consequences, from disability to child death. There are many ways of cytomegalovirus transmission: airborne, parenteral, domestic contact, sexual and 
vertical (transplacentally, with aspiration of secretions from the birth canal and natural feeding). The virus is able to have a direct and indirect effect on 
the body. It is able to independently induce immunosuppression. The article describes the epidemiological data, pathogenesis, clinical manifestations, 
and modern methods of diagnosis, treatment and prevention of cytomegalovirus infection. Also, some diagnostic problems in immunosuppressive 
organisms are described.
Conclusions: Due to its consequences, namely, children`s disability, death and immunosuppressed people, cytomegalovirus has become a demographic 
problem. A high infection frequency indicates a low level of social development of the population. More public awareness is needed on the transmission 
and possible consequences of cytomegalovirus infection.
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the “defect” appears in the body’s immune system. The in-
crease in the number of people with immunodeficiency is 
of current interest. These include people who take immu-
nosuppressants and cytostatics, patients who suffer from 
malignant neoplasms and HIV infection [3, 9]. Studies have 
shown that the development of CMVI during the treatment 
with cytostatics results in death in 80% of cases [10]. CMV 
is one of the most common infections which cause pathol-
ogy in the fetus and newborns, which, in turn, leads to seri-
ous consequences, from disability to child death [11]. This 
indicates the presence of a demographic problem. The in-
fection of the pregnant women during the first trimester of 
pregnancy is especially dangerous. Such cases are less com-
mon, but the fetus pathology is very pronounced [9, 12]. 
The exacerbation of chronic infection and superinfection 
with another strain of CMV is also dangerous [3]. It has 
been established that during blood transfusion and organ 
transplantation, CMV infection can also be transmitted.
History
In 1881, at a meeting of the Society of Physicians of the 
Lower Rhine region, the German pathologist H. Ribbert, 
for the first time described the histological picture of the 
neonatal nephritis with congenital syphilis. He found hy-
pertrophied renal tubules with unusual giant cells contain-
ing nuclear inclusions. He suggested a protozoan etiology 
of the inclusion.  In 1904 he described similar cells in other 
neonatal organs. In 1920–21 E. Goodpasture and P.Talbert 
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suggested that the etiology of this infection was viral, since 
the lesion was similar to herpes virus and chickenpox vi-
rus. The changes in the normal epithelial cells found in the 
liver, kidneys and lungs are due to chronic inflammation. 
This characteristic picture was called “cytomegaly”. In 1925, 
for the first time, such cells were found in the body of an 
adult, viz. in a man who died as a result of complications 
of liver abscess and ulcerative colitis. In 1926 Cole and 
Kuttner found similar changes in the salivary glands of rats 
and gilts. The unsuccessful attempt to infect other animal 
tissues with infected human secretions proved the specific-
ity of tropism specifically to the salivary gland epithelium. 
Fetterman (1952) found that cytomegalic inclusions can be 
discharged during the whole life, being found in the urine. 
In 1954 Smith isolated a pure virus culture from the salivary 
gland epithelium in rats, and later from the human salivary 
glands. Rowe found this virus in the adenoids of children. 
In subsequent years, intracellular inclusions characteristic 
of cytomegaly were found in the tissues of the liver, spleen, 
brain, retina of sick newborns and infants. Clinically, these 
changes manifested as hepatosplenomegaly, icterus, chorio-
retinitis, microcephaly with mental retardation, motor dis-
orders, cerebral calcification. In 1960 Weller introduced a 
new nosology – cytomegalovirus infection. In 1960-1970, 
due to the active study of this pathogen, the modes of trans-
mission (natural and artificial) were determined, and the 
fact that most people remain infected after initial contact 
[13, 14, 15].
Epidemiology
Human is the only natural source of CMV infection. 
The age of CMV infection depends on the geographical lo-
cation, socioeconomic status, culture and education of the 
population. In developing countries most children become 
infected with CMV infection in the first years of life, there-
fore, in early youth, 100% of the adult population is sero-
positive. In developed countries, only 50% of young people 
of intermediate socioeconomic status are seropositive. This 
observation has important implications for the epidemiol-
ogy of congenital CMVI. Inasmuch as a CMV- seronega-
tive woman of childbearing age has a serious risk to be in-
fected during pregnancy, this can cause a high probability 
of  intrapartum infection of the fetus as well as the birth 
of a baby with some congenital infection symptoms. Cas-
es of congenital CMVI in infants from mothers who have 
been infected before pregnancy are caused by reactivation 
or reinfection with another virus strain. Its main biological 
properties have a lifelong persistence (in the vascular endo-
thelium, liver, spleen, salivary glands, brain and kidneys), 
and reactivation in the human immunosuppressed organ-
ism [7, 16, 17]. It is important to note that there are many 
ways of CMV transmission: airborne, parenteral, household 
contact, sexual and vertical (transplacentally, aspiration of 
secretions from the birth canal and breastfeeding). This in-
fection is also called “kissing disease”, as it is often transmit-
ted through sexual contact, therefore it can be considered 
a problem of young people [18]. In turn, blood transfusion 
and organ transplantation are also important ways of CMV 
transmission. Thanks to blood screening, the number of 
cases of morbidity and mortality of premature babies was 
reduced due to transfusion-induced CMV infection [13]. 
According to some researchers, infectious diseases are de-
tected in 50-60% of full-term newborns and 70% of pre-
mature newborns [19]. CMVI is one of the most common 
intrauterine infections that cause severe pathology, even 
the child death [11]. More than 50% of breast-fed infants 
of CMV-seropositive mothers are infected with CMV [20]. 
The uninfected children have a high risk of infection in kin-
dergarten. According to some studies, about 80% of pre-
school children are CMV-seropositive. After all, the virus 
is easily transmitted to susceptible children through saliva, 
urine and other contaminated objects. Being infected in the 
kindergarten, children can transmit the infection to their 
parents [21, 22], which plays an important role in the epide-
miology of CMV infections in young parents [23]. It is con-
sidered that the sexual transmission of CMV is prevalent in 
the adult population [18], but given the fact that the virus is 
found in saliva, vaginal secretions and semen, it is difficult 
to determine which particular way of transmission prevails. 
Serodiagnosis of donor and recipient blood before and after 
transfusion is evidence, that CMV is also transmitted paren-
terally. A research was conducted on blood screening before 
transfusion. It revealed that the rate of CMV transmission 
to premature newborns was reduced [13]. Often, the clini-
cal manifestations of CMVI are found in previously infected 
individuals, which is the reactivation of the latent form or 
reinfection with a new strain. In HIV patients, cytomega-
lovirus affects the organs during the stages of progressive 
immunosuppression, viz, in the AIDS stages, which either 
do not receive or do not respond to antiretroviral therapy 
(ART). Other risk factors include the presence of associated 
opportunistic infections (pneumocystic pneumonia, toxo-
plasmosis, histoplasmosis, tuberculosis, etc.), high levels of 
CMV and HIV viremia in plasma [24].
Morphological and biological features of CMV
Cytomegalovirus: Herpesviridae family, Bethaherpes-
viridae subfamily, Cytomegalovirus genus [25]. Morpho-
logical and biological properties are similar to herpes sim-
plex virus type 1. CMV belongs to the human herpes virus 
type 5. CMV has the largest double-stranded linear DNA 
genome from the entire Herpesviridae family. The virus 
consists of an icosahedral capsid covered with a tegument 
and a bilipid outer envelope [13, 26].The approximate size of 
spheric virion is 200-300 nm [26]. The cubic nucleocapsid 
contains 162 of capsomers. The surface and capsid glyco-
proteins are distinguished in the virus structure. The gly-
coproteins gB, gO, gN, gH, gL, located on the membrane 
surface, are involved in the attachment and penetration into 
the host cells. Protein gB is the initiator of attachment [27]. 
The remaining glycoproteins are involved in the cell-virus 
immune response [27]. The proteinkinase is found in CMV. 
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It phosphorylates ganciclovir (antiviral drug), which is very 
important in the treatment of CMVI. When a kinase mu-
tates, the resistance to therapy develops [13, 28]. CMV is 
characterized by: low virulence, the ability to suppress cel-
lular immunity, a long cycle of reproduction and the lowest 
cytopathogenic activity, in contrast to herpes simplex virus. 
Like other representatives of herpes viruses, CMV has the 
ability to infect mononuclear cells and lymphocytes. It rep-
licates in cell culture (in vivo), but slowly [26]. 
CMV is able to encode more than 200 protein structures 
[13]. The functions of most of these proteins remain un-
clear, but it is known that they are divided into functional 
and structural proteins. Some functions of the functional 
proteins have been established: UL16 protein inhibits natu-
ral killer (NK) cells; UL24 induces cell cycle arrest; TRS1 
inhibits the process of autophagy of affected cells; UL36 in-
hibits cell apoptosis; US2 destroys the components of the 
major histocompatibility complex (MHC) class 2, prevent-
ing the recognition of CD4 + lymphocytes; US3 prevents 
maturation and transport of  MHC class 1 molecules; phos-
phoprotein 65 (pp65), located in the tegument, inhibits the 
cascade of interferon production, which provides an inborn 
antiviral immunity [26].
Pathogenesis
CMV has a direct effect on the body. Using the above 
surface glycoproteins, it attaches to specific receptors of the 
cytoplasmic membrane of the host cell [26]. In respect of 
the vital activity of the virus, the intracellular parasitiza-
tion is necessary, as it has adapted itself to penetrate the 
cells through a few ways [26]. CMV penetrates through 
viropexis or fusion of capsid with cytoplasmic membrane. 
Being inside the cell, virus replication begins, which con-
sists of 3 phases. The super early phase lasts 2-4 hours after 
infection. During this period nucleocapsid proteins are syn-
thesized to ensure penetration into the nucleus and onset 
of viral replication. The viral nucleocapsid DNA activates 
the major immediate early gene (IE). This gene encodes a 
protein that is the main regulator of virus transcription and 
activation. During replication, antigens are synthesized and 
accumulated in the nucleus, viz. the virus grows up. Next 
the 24 hour early phase ensues. It begins with the synthe-
sis of a new viral DNA, DNA polymerase and enzymes that 
are necessary for the production of new virions. As a result, 
the newly replicated DNA is coated with a capsid. Then the 
late phase begins, namely, the escape of the virus into the 
cytoplasm of the host cell. Here it is enriched with the sec-
ondary coat – envelope. The envelope is synthesized in the 
endoplasmic reticulum and the Golgi apparatus [13, 14, 26]. 
Depending on the type of the affected cell, 2 variants of late 
phase development are possible, but the result in both cases 
is cell lysis. In the epithelium of mucous membranes – virus 
exocytosis occurs, while in lymphocytes, monocytes and fi-
broblasts – latent persistence is found. In the late period, the 
virus cannot be recognized due to a weak expression of IE 
gene [26, 27, 28, 29]. The activation of the infectious process 
can occur with the differentiation of monocytes into mac-
rophages. This occurs during an active infectious process. 
The viral fragments are recognized by professional antigen-
presenting cells, namely dendritic cells, macrophages, B- 
lymphocytes, CD8 + and CD4 + lymphocytes. Being acti-
vated, they release pro-inflammatory cytokines and activate 
NK and antigen-specific T-helpers. In turn, NK lyses cells in 
which the MHC class 1 disappeared due to the virus. Pathol-
ogies resulting from direct action are described in the sec-
tion Clinical manifestations. CMV also has an indirect effect 
on the body, causing its immunosuppression via the follow-
ing mechanisms: 1) preventing the antigen presentation of 
CD8+ and CD4+ cells, viz., suppressing their cytotoxicity; 
2) preventing the expression of MHC 1-2 molecules on the 
cell surface; 3) viral protein blocking of the cytotoxic action 
of NK [12]. Due to the suppression of T-lymphocytes and B-
lymphocytes functions, the antibody synthesis diminishes 
(IgM, IgG). This misleading aspect results in diagnosis dif-
ficulties.  A discordance is observed between the patient’s 
condition and the process activity, especially in cases of 
AIDS and allogeneic immunosuppressions [30]. This mani-
fests as transplant rejection and superinfection [10].
Clinical manifestations
Clinical manifestations are very variable due to the tro-
pism to the multitude of body tissues, as well as different 
sensitivity of these tissues to the virus action. This is not un-
commonly misleading when making diagnoses, being dis-
guised as other nosologies. The epithelium of the mucous 
membranes of the respiratory and intestinal tracts is the 
most sensitive, as well as the epithelium of the bile ducts, 
neuroglial and hematopoietic cells.
CMV in immunotolerant humans, is manifested as CMV 
mononucleosis or sialoadenitis. CMV mononucleosis be-
gins with general symptoms of intoxication, fever, as well 
as sore throat and pain in the projection area of the salivary 
glands. Objectively, swollen cervical and submandibular 
lymph nodes are determined and enlarged liver by2-3 cm 
from the costal arch. In sialoadenitis, on the background of 
subfebrile temperature, the parotid salivary glands are bilat-
erally impaired.
In children, depending on the infection period, CMV 
can manifest itself in several forms: 1) congenital (intra-
uterine infection), the symptoms appear in the first 2 weeks 
of life; 2) perinatal (infection during childbirth or neonatal 
period); 3) acquired (infection of children from 1 month to 
2-5 years) [13, 31]. In the congenital form, 90% of babies 
lack clear signs of CMVI. This happens when an infected 
woman gets pregnant. Such children have a high risk of de-
veloping complications, such as developmental delay and 
neurosensory deafness. The frequency of the latter is about 
15%, [32, 33]. In the congenital form, only 10% of newborns 
have obvious symptoms of CMV lesion. Of these, 40–90% 
have hepatitis, neurological disorders, developmental delay, 
cerebral palsy, microcephaly, and mental retardation [34, 
35, 36]. The cases of sensorineural hearing loss amount to 
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about 35-65% [37]. This type of CMVI is called “cytome-
galic inclusion disease”. This type also develops in the case 
of primary infection of the mother during pregnancy. The 
aspect of the newborn is “blueberry muffin baby”, due to 
the defeat of the hematopoiesis cells and the development 
of thrombocytopenic purpura [13]. The CNS impairment 
occurs, namely, cerebral atrophy, chorioretinitis with op-
tic nerve atrophy, microcephaly, ventriculomegaly and the 
presence of intracerebral calcificates. At the same time, a 
little more than 30% of newborns are premature. Different 
combinations of syndromes are characteristic [38, 39, 40].
Sucking and swallowing disorders are objectively revealed, 
as well as strabismus, epileptic seizures, paraparesis, plegia 
and muscular hypotonia is replaced by hypertension. There 
is an assumption that CMV influences the development of 
neurological symptoms in Down`s syndrome [41]. In the 
case of perinatal infection some conditions are characteris-
tic, such as neonatal cholestatic hepatitis, hematological dis-
orders, lymphadenopathy, focal nephritis and pneumonitis 
(viz., atypical inflammation of lung tissues). In acquired in-
fection, mononucleosis syndrome, acute CMV hepatitis, or 
prolonged fever syndrome are possible. The outcome of an 
acute process in any tissue is the formation of calcifications 
and interstitial fibrosis [42].
In patients with post-transplant immunosuppression, any 
kind of CMV infection has a more severe course with a high 
incidence of lethal outcome, and usually occurs in the first 
120 days after the intervention. The clinical manifestations 
depend on the type of transplant and the degree of immu-
nosuppression. Bone marrow recipients most often develop 
interstitial pneumonia, hepatitis, and esophago-gastro-duo-
denal impairment. In the case of recipients of solid organs, 
the transplanted organs are mainly affected. The symptoms 
of the affected organ are associated with fever of unknown 
origin and typical for CMV changes in the overall blood 
picture [43]. In liver transplantation, the differential diag-
nosis of rejection and CMV hepatitis is difficult [10, 43].
In HIV-infected persons, the eyeball tissue is usually the 
first to be affected. Most often the process is bilateral, espe-
cially in the absence of ART, the level of CD4 + is<50 cells 
/ mm3and the immune recovery syndrome develops. CMV 
retinitis does not always begin with scotomas, decreased vi-
sual acuity, photophobia, loss of visual field and the appear-
ance of “floating flies” before eyes [28, 35]. Sometimes the 
symptoms may be absent. But when examining the retinal 
fundus, the “omelette with ketchup” symptom is always de-
tected [35], which are perivascular yellow-white infiltrates 
with hemorrhages [28, 35]. When there is immune recovery 
syndrome, vitreitis may develop, that is, the inflammation 
of the vitreous body. This syndrome usually manifests 1-3 
months after the onset of highly active ART. The reduced 
visual acuity and vision loss, as complications in these cases, 
result from cataracts, retinal detachment, cystoid macular 
edema, or damage to the zone 1 of the cerebral cortex [35]. 
Colitis occurs in 5-10% of HIV-infected people in AIDS 
stage. Such symptoms as severe weakness, fever, abdominal 
pain, profuse diarrhea, weight loss, and anorexia are char-
acteristic. Some complications can occur, such as intestinal 
hemorrhage and perforation of the intestinal walls. CMV-
esophagitis is rare, being accompanied by fever, odyno-
phagia, localized retrosternal pains and nausea [28, 35]. To 
make the diagnosis of CMV pneumonitis, several criteria 
must be considered: 1) the presence of interstitial infiltrates 
in the lungs on a radiograph or CT scan; 2) intracellular in-
clusions in the lung tissues (typical for CMV); 3) the ab-
sence of another pathogen that can cause pneumonitis [35]. 
The damage to the nervous system is clinically manifested 
as dementia, myeloradiculitis and ventriculo-encephalitis 
[28, 35]. At the same time, they are obligate in CSF mono-
nuclear pleocytosis and proteinuria [35]. The association 
with the following symptoms determines the process nature 
and localization. The appearance of fever, drowsiness and 
impaired consciousness indicates the development of de-
mentia. Disturbances of consciousness can result in reduced 
attention and memory, delirium, spatial and/or temporal 
disorientation. The appearance of progressive paresis of the 
lower extremities and dysfunction of the pelvic sphincters 
subsequently indicates myeloradiculitis. In ventriculoen-
cephalitis, in addition to ataxia, nystagmus, progressive de-
lirium and cranial nerves lesions, MRI revealed signal am-
plification in the periventricular zone [44].
Laboratory diagnosis
Studies are performed on certain groups of patients: 1) 
women who are pregnant or who are planning their preg-
nancy, with the history of miscarriages, congenital malfor-
mations and stillbirths; 2) pregnant women diagnosed with 
hepatitis, hepatosplenomegaly, fever of unknown origin, or 
detected by ultrasound, symptoms of intrauterine infection; 
3) patients with immunodeficient conditions (HIV, cancer, 
treatment with immunosuppressants, hemodialysis, etc.); 4) 
children with congenital or acquired CMVI symptoms; 5) 
all patients with sepsis, meningoencephalitis, severe pneu-
monia, hepatitis, impairment of the digestive tract and eyes 
[45, 46, 47]; 6) donor and recipient of blood components, 
organs, tissues and sperm before each donation; 7) history 
of sexual contact with a seropositive partner.
Methods of laboratory diagnosis
Virusoscopic method. The main morphological feature, 
active infection – giant cells with intranuclear and intracy-
toplasmic inclusions, “cytomegaly.” This symptom is found 
only in 50% of cases.
 Virological method. Almost any body fluid or tissue 
can be cultivated. The culture for the virus should consist of 
a single layer of human embryonic fibroblasts and a double 
layer of human lung cells. The cultivation duration is up to 
6 weeks.
Serological methods. Their essence is to identify viral 
antigens (Ag) interacting with each other and antibodies 
(Ab) produced by the body against them. Enzyme-linked 
immunosorbent assay (ELISA) is the most common and 
affordable test. It determines the degree of avidity and the 
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presence of CMV antibodies of classes IgA, IgM and IgG. 
(Avidity is the stability of Ag-Ab immunocomplexes, which 
characterizes the antibodies activity). In 5-7 days, after the 
initial infection Ab IgM appear in the blood and persist for 
1-2 months [44]. After 10-14 days of infection, low-avid IgG 
appear. Within 1–3 months, high-avid IgG appear and grow, 
and remain in the blood for the entire life [48]. When the 
process is reactivated, the hyperproduction of IgA is more 
typical than IgM. The presence of low avid antibodies in-
dicates a primary infection, and a highly avid infection, a 
reactivation or latent infection. To establish the process ac-
tivity, ELISA is repeatedly carried out, in order to determine 
the follow-up changes in the level of Abs [49]. It is to be 
noted that this method does not always reflect the real state 
of the patient. As in the immunodeficiency conditions, the 
immune system is not able to produce a sufficient amount of 
antibodies, which can be regarded as a low process activity 
[30]. If a congenital infection is suspected, antibodies are 
detected in the blood in the first 3 weeks after birth. Other-
wise,  Ab can be detected after 3 weeks, as a result of natural 
feeding with infected CMV milk [13]. Immunofluorescence 
(IF) reactions are used to establish the infectious process 
activity. IF is based on the detection of fluorescent Abs. Ab 
labeled with fluorochrome do not lose the ability to connect 
with the corresponding Ag and thereby cause a blue-violet 
glow. The presence of antigen luminescence in the nucleus 
and cytoplasm of cells reveals pp72 and pp65 proteins [49]. 
Another method of indirect immunofluorescence is applied 
after 12-24 hours of cultivation in a test tube, centrifuged 
and stained with monoclonal CMV-specific antibodies. This 
method is much more sensitive and accelerates the duration 
of the study [50, 51]. Also, researchers carry out reactions of 
binding complement and indirect hemagglutination.
Molecular biological method is a specific and highly 
sensitive study, and it is used as the main method of diag-
nosing CMVI as an opportunistic infection [52, 53]. The 
viral DNA genome is determined by the polymerase chain 
reaction (PCR). It is possible to determine the viral load, 
which is important in determining the follow-up treatment 
efficacy. Both latent and active infections are detected. The 
presence of DNA in the blood and urine indicates a high 
viral activity, i.e. the presence of CMV, while the DNA pres-
ence only in saliva, and indicates an infection [54]. The 
presence of CMV DNA in the amniotic fluid indicates 100% 
damage to the fetus [53]. 
Cytological method – its positive result proves the pres-
ence of CMVI in 100%. The virus can be detected in all the 
body secretions, CSF, urine, tissue biopsies. The staining of 
biomaterial smears and tissue sections is carried out using 
dyes (hematoxylin-eosin or Romanovsky-Giemsa). Specific 
cells, cytomegalovirus, containing large intranuclear and 
cytoplasmic inclusions, similar to the owl’s eye, are identi-
fied in various shapes and sizes. They contain a breeding 
virus inside. 
Histological examination is the “gold standard” in ob-
stetrics. The placenta study determined its hyperplasia, cy-
tomegaly, thrombosis and focal ischemic infarctions, fibri-
noid necrosis of the chorionic villi stroma and damage to 
the basal decidual cells [51]. But the method has a number 
of drawbacks: low sensitivity of intravital diagnosis, that is 
why, a negative result requires the biomaterial test to be re-
peated daily for 3-5 days. This study is effective only at the 
infectious process peak.
Treatment
The treatment method depends on the age, the immune 
system state and the presence of associated conditions. Cur-
rently, only antiviral nucleoside drugs and a specific human 
anti-cytomegalovirus immunoglobulin have shown their 
antiviral efficacy in evidence-based medicine. The immu-
noglobulin containing donor IgM CMV provides passive 
immunity [54].
The indications for the use of immunoglobulin are pre-
vention in and treatment of: pregnant women with acute 
CMV infection during the initial infection (IgM and IgG are 
present in the blood); pregnant women with active CMV 
infection (detection of CMV DNA, IgM in the blood and 
urine, CMV DNA in the amniotic fluid); newborns and 
children under 3 years old, with CMV DNA found in the 
biomaterial in the first 2 weeks of life; premature or hypo-
trophic newborns and children under 3 years old with in-
tranatal infections; children with active CMV (CMV DNA 
in blood); patients before transplantation; recipients in the 
post-transplantation period [55].
Children under 3 years of age are administered 1 mg / kg 
once every 48 hours (6 times) [55]. Anti-cytomegalovirus 
immunoglobulin is intravenously administered 150 mg / kg 
72 hours before transplantation and in the next 2, 4, 6, 8 
weeks after transplantation, and in 12 and 16 weeks, 50-100 
mg [8].
The first-line antiviral drugs include ganciclovir and 
valganciclovir, the second is foscarnet and cidofovir. Ganci-
clovir is a synthetic analogue of purine and is converted by 
phosphotransferase (UL 97) and other enzymes in infected 
host cells to ganciclovir triphosphate. The latter, in turn, is 
embedded in the synthesized viral DNA. This leads to the 
termination of CMV replication. This drug has proven to be 
highly effective against the rest of herpes viruses. Valganci-
clovir is ether and a prodrug of ganciclovir. Valganciclovir 
has an advantage: its oral absorption and bioavailability are 
the same as the intravenous administration of ganciclovir 
[56]. The disadvantages of these drugs are: prolonged ther-
apy causes the development of resistance, due to the muta-
tion of UL97 [13, 28], and the suppression of hematopoi-
esis, especially leukocytes [57]. Ganciclovir is administered 
intravenously 5 mg / kg every 12 hours for 14-21 days, or 6 
mg / kg orally per day for 5 days (+ 100-120 days after the 
transplant). Valganciclovir, 900 mg per day for 14-21 days. 
Foscarnet- pyrophosphate compound inhibits herpes virus 
DNA polymerase. It differs from previous drugs, namely, it 
does not need phosphorylation for its activity. Also, it inhi- 
bits HIV retrotranscriptase. Disadvantages: only endove-
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nous route of administration, reduced levels of calcium, 
magnesium, potassium, blood phosphorus and nephrotox-
icity. It is administered 60 mg / kg every 8 hours for 2–3 
weeks, afterwards 90–120 mg / kg. Cydofovir is a synthetic 
nucleoside analogue which stops the synthesis of viral DNA 
by inhibiting DNA polymerase. It is active not only against 
herpes viruses, but also human papilloma viruses, pox vi-
ruses and adenoviruses. Intravenous administration – 5 mg 
/ kg per week for 2 weeks in a row.
Indications for the administration of antiviral drugs are: 
treatment of CMV retinitis, prevention of CMV intrans-
plant recipients, prevention of CMVI in HIV-infected peo-
ple (ganciclovir for adults and children only), treatment of 
CMV colitis, esophagitis.
Prevention
Non-specific prophylaxis includes public awareness of 
transmission routes, risks of infection, and consequences 
for children and immunocompromised people.
Pregnant women should avoid contact with CMV in-
fected children. After the birth of the fetus with CMVI, it is 
necessary to keep a 2 year pause until the next pregnancy. 
Measures should be taken to identify seronegative pregnant 
women and their laboratory monitoring.
The Federal Agency of the USA Department of Health 
Centers for Disease Control and Prevention (CDC) was cre-
ated in 1946 in the state of Georgia, and its role is to ensure 
the protection of public health by providing information in 
order to improve health care solutions. It made recommen-
dations on the need to raise awareness of the population, 
especially women of childbearing age for the specific pre-
vention of CMV. In 2000 the National Medical Academy of 
the United States of America published an article about the 
high priority of developing a vaccine against CMV, which 
has become a big stimulus for vaccine manufacturers.
At present, still there is no officially specific prevention, 
but active research is underway to develop a vaccine against 
CMV. But there are several recombinant CMV vaccines un-
dergoing clinical trials. It was found that women vaccinated 
with recombinant gB were 50% less likely to become infect-
ed compared to women who received placebo [58].
There were identified 4 groups of patients in need of a 
vaccine against CMV: CMV seronegative and CMV sero-
positive women of childbearing age, seronegative recipients 
of solid organs and bone marrow obtained from CMV sero-
positive donors [59].
Conclusions
1. Cytomegalovirus infection is very common and poses 
a great danger to people with low immunity and children.
2. The infection frequency indicates a low level of social 
development of the population.
3. Currently, there is an increase in the infection rate all 
over the world, which is connected both with the improve-
ment of the diagnosis quality and real disease growth.
4. The study of CMVI characteristics is rapidly develo-
ping, although some issues concerning diagnosis, treatment 
and prevention are still open: expensive diagnosis and treat-
ment, lack of vaccine.
5. According to the CDC recommendations, more ex-
tensive public information is needed, especially for young 
women of childbearing age.
6. It is also necessary to pay great attention to CMV 
study in the training of doctors in the Republic of Moldova.
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